Key Points
- Director Christopher Patusky sold 1,000 shares on April 17 at an average price of $578.88 for roughly $578,880, leaving him with 1,490 shares (a 40.16% reduction in his holding).
- Material insider selling by senior executives may pressure sentiment — CEO Martine Rothblatt sold 9,500 shares (~$5.5M on April 15) and EVP Paul A. Mahon sold 8,300 shares (~$4.79M on April 16).
- Market and analyst context: UTHR trades near $588 with a market cap around $25.8B and a P/E ~21, while analysts have raised targets and the consensus is a "Moderate Buy" with an average target of $601.50.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Christopher Patusky sold 1,000 shares of the company's stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $578.88, for a total value of $578,880.00. Following the sale, the director owned 1,490 shares in the company, valued at approximately $862,531.20. This represents a 40.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
United Therapeutics Trading Up 1.4%
UTHR stock opened at $588.38 on Friday. The company's 50 day moving average is $526.73 and its 200 day moving average is $489.49. The stock has a market cap of $25.79 billion, a price-to-earnings ratio of 21.09, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the prior year, the business earned $6.19 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the stock. TD Cowen upped their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a "buy" rating in a research report on Monday, March 30th. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Wells Fargo & Company upped their target price on United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 31st. HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $601.50.
Read Our Latest Research Report on United Therapeutics
Institutional Trading of United Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. Asset Advisory Group Inc. boosted its stake in shares of United Therapeutics by 19.8% during the first quarter. Asset Advisory Group Inc. now owns 630 shares of the biotechnology company's stock valued at $374,000 after purchasing an additional 104 shares during the period. Nations Financial Group Inc. IA ADV boosted its stake in shares of United Therapeutics by 1.8% during the first quarter. Nations Financial Group Inc. IA ADV now owns 4,116 shares of the biotechnology company's stock valued at $2,441,000 after purchasing an additional 72 shares during the period. Rockefeller Capital Management L.P. boosted its stake in shares of United Therapeutics by 10.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company's stock valued at $645,000 after purchasing an additional 127 shares during the period. Corient Private Wealth LLC boosted its stake in shares of United Therapeutics by 13.5% during the fourth quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company's stock valued at $9,379,000 after purchasing an additional 2,289 shares during the period. Finally, Rehmann Capital Advisory Group boosted its stake in shares of United Therapeutics by 9.8% during the fourth quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company's stock valued at $1,767,000 after purchasing an additional 324 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.
United Therapeutics News Summary
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Unusual bullish options flow — Traders bought 15,930 UTHR call options on Friday (about a 665% jump versus average call volume), indicating speculative or hedged bullish positioning that can amplify near-term upside or volatility.
- Positive Sentiment: Analyst target increases and constructive coverage — Multiple firms have raised price targets recently (examples cited include Morgan Stanley, Oppenheimer, BofA and RBC) and the consensus remains a "Moderate Buy" with an average target near $601.50, supporting positive investor sentiment. Analyst Coverage & MarketBeat Summary
- Neutral Sentiment: Small CEO sale disclosed — CEO Martine Rothblatt sold 75 shares (March 13) for roughly $40k; the size is immaterial to overall ownership and is unlikely on its own to drive stock direction. InsiderTrades Alert
- Neutral Sentiment: Institutional/hedge fund activity — Several funds adjusted positions (some added, some trimmed); UTHR remains heavily institutionally owned (~94%), which tends to moderate retail-driven swings. MarketBeat: Insider & Institutional Activity
- Negative Sentiment: Material insider selling by CEO — Martine Rothblatt sold 9,500 shares on April 15 (~$5.5M at ~$580.36), a significant reduction in her reported holding per filings; large insider sales can be perceived negatively by investors. SEC Filing: CEO Sale
- Negative Sentiment: Large EVP sale — EVP Paul A. Mahon sold 8,300 shares on April 16 for roughly $4.79M, a meaningful insider disposition that may pressure sentiment if more insider sales follow. SEC Filing: EVP Sale
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
